Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A busy fourth quarter
January 2019
SHARING OPTIONS:

CRANBURY, N.J.—Oncobiologics Inc. ended 2018 with news of several changes, primary among them being a name change from Oncobiologics to Outlook Therapeutics Inc. The company also launched its first human clinical study for its ONS-5010 program in wet age-related macular degeneration. In addition, Oncobiologics’ executive leadership team saw two new hires: Jeff Evanson as chief commercial officer, and Terry Dagnon as chief operating officer, both of whom bring more than 20 years of experience with them. Evanson has served as managing director in the Life Science Practice of Navigant, founder and president of Scott Three Consulting LLC, and vice president and global commercial head of the Pharmaceutical Franchise at Novartis. Dagnon held the position of senior vice president of operations at Dohmen Life Science Services most recently, and previously was the North America head of regulatory affairs at Alcon, a Novartis company.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.